MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Shoaib Afzal; B Vainer; Søren Astrup Jensen; Ulla Birgitte Vogel; J P Matsen; J B Sørensen; Per Kragh Andersen; H E Poulsen

doi:10.1093/annonc/mdp046

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Shoaib Afzal
, B Vainer
, Søren Astrup Jensen
, Ulla Birgitte Vogel
, J P Matsen
, J B Sørensen
, Per Kragh Andersen
, H E Poulsen

79 Citations (Scopus)

Abstract

Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.

Original language	English
Journal	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume	20
Issue number	10
Pages (from-to)	1660-6
Number of pages	7
DOIs	https://doi.org/10.1093/annonc/mdp046
Publication status	Published - 1 Oct 2009

Access to Document

10.1093/annonc/mdp046

Cite this

@article{cda518f8848b45dc8e48c81b49bcf3ff,

title = "MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer",

abstract = "Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.",

author = "Shoaib Afzal and B Vainer and Jensen, \{S{\o}ren Astrup\} and Vogel, \{Ulla Birgitte\} and Matsen, \{J P\} and S{\o}rensen, \{J B\} and Andersen, \{Per Kragh\} and Poulsen, \{H E\}",

year = "2009",

month = oct,

day = "1",

doi = "10.1093/annonc/mdp046",

language = "English",

volume = "20",

pages = "1660--6",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "1569-8041",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

AU - Afzal, Shoaib

AU - Vainer, B

AU - Jensen, Søren Astrup

AU - Vogel, Ulla Birgitte

AU - Matsen, J P

AU - Sørensen, J B

AU - Andersen, Per Kragh

AU - Poulsen, H E

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.

AB - Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.

U2 - 10.1093/annonc/mdp046

DO - 10.1093/annonc/mdp046

M3 - Journal article

C2 - 19465420

SN - 1569-8041

VL - 20

SP - 1660

EP - 1666

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 10

ER -

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Abstract

Access to Document

Fingerprint

Cite this